We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 05, 2021

Impact of Early Discontinuation/Dose Modification of Venetoclax on Outcomes in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Haematologica

 

Additional Info

Disclosure statements are available on the authors' profiles:

Haematologica
The Impact of Early Discontinuation/Dose Modification of Venetoclax on Outcomes in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Post-Hoc Analyses From the Phase III MURANO Study
Haematologica 2020 Dec 17;[EPub Ahead of Print], AR Mato, JP Sharman, JML Biondo, M Wu, Y Mun, SY Kim, K Humphrey, M Boyer, Q Zhu, JF Seymour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading